skip to content
Thank you for visiting First Coast Service Options' Medicare provider website. This website is intended exclusively for Medicare providers and health care industry professionals to find the latest Medicare news and information affecting the provider community.
To enable us to present you with customized content that focuses on your area of interest, please select your preferences below:
Select which best describes you:
Select your location:
Select your line of business:

By clicking Continue below you agree to the following:

LICENSE FOR USE OF "PHYSICIAN'S CURRENT PROCEDURAL TERMINOLOGY" (CPT), FOURTH EDITION End User/Point and Click Agreement: CPT codes, descriptions and other data only are copyright 2022 American Medical Association (AMA).

All Rights Reserved (or such other date of publication of CPT). CPT is a trademark of the AMA.
You, your employees, and agents are authorized to use CPT only as contained in the following authorized materials:
Local Coverage Determinations (LCDs),
Local Medical Review Policies (LMRPs),
Bulletins/Newsletters,
Program Memoranda and Billing Instructions,
Coverage and Coding Policies,
Program Integrity Bulletins and Information,
Educational/Training Materials,
Special mailings,
Fee Schedules;

internally within your organization within the United States for the sole use by yourself, employees and agents. Use is limited to use in Medicare, Medicaid, or other programs administered by the Centers for Medicare and Medicaid Services (CMS), formerly known as Health Care Financing Administration (HCFA). You agree to take all necessary steps to insure that your employees and agents abide by the terms of this agreement. Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CPT for resale and/or license, transferring copies of CPT to any party not bound by this agreement, creating any modified or derivative work of CPT, or making any commercial use of CPT. License to use CPT for any use not authorized here in must be obtained through the AMA, CPT Intellectual Property Services, 515 N. State Street, Chicago, IL 60610. Applications are available at the AMA website. Applicable FARS/DFARS restrictions apply to government use.

AMA Disclaimer of Warranties and Liabilities CPT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CPT. The AMA does not directly or indirectly practice medicine or dispense medical services. The responsibility for the content of this file/product is with CMS and no endorsement by the AMA is intended or implied. The AMA disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This agreement will terminate upon notice if you violate its terms. The AMA is a third party beneficiary to this agreement.

CMS Disclaimer: The scope of this license is determined by the AMA, the copyright holder. Any questions pertaining to the license or use of the CPT must be addressed to the AMA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CPT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL CONTAINED ON THIS PAGE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

AMA - U.S. Government Rights

This product includes CPT which is commercial technical data and/or computer data bases and/or commercial computer software and/or commercial computer software documentation, as applicable which were developed exclusively at private expense by the American Medical Association, 515 North State Street, Chicago, Illinois, 60610. U.S. Government rights to use, modify, reproduce, release, perform, display, or disclose these technical data and/or computer data bases and/or computer software and/or computer software documentation are subject to the limited rights restrictions of DFARS 252.227-7015(b)(2)(June 1995) and/or subject to the restrictions of DFARS 227.7202-1(a)(June 1995) and DFARS 227.7202-3(a )June 1995), as applicable for U.S. Department of Defense procurements and the limited rights restrictions of FAR 52.227-14 (June 1987) and/or subject to the restricted rights provisions of FAR 52.227-14 (June 1987) and FAR 52.227-19 (June 1987), as applicable, and any applicable agency FAR Supplements, for non-Department Federal procurements.

ADA CURRENT DENTAL TERMINOLOGY, (CDT)
End User/Point and Click Agreement: These materials contain Current Dental Terminology (CDTTM), Copyright © 2016 American Dental Association (ADA). All rights reserved. CDT is a trademark of the ADA.

THE LICENSE GRANTED HEREIN IS EXPRESSLY CONDITIONED UPON YOUR ACCEPTANCE OF ALL TERMS AND CONDITIONS CONTAINED IN THIS AGREEMENT. BY CLICKING ON THE BUTTON LABELED "ACCEPT", YOU HEREBY ACKNOWLEDGE THAT YOU HAVE READ, UNDERSTOOD AND AGREED TO ALL TERMS AND CONDITIONS SET FORTH IN THIS AGREEMENT.

IF YOU DO NOT AGREE WITH ALL TERMS AND CONDITIONS SET FORTH HEREIN, CLICK ON THE BUTTON LABELED "DECLINE" AND EXIT FROM THIS COMPUTER SCREEN.

IF YOU ARE ACTING ON BEHALF OF AN ORGANIZATION, YOU REPRESENT THAT YOU ARE AUTHORIZED TO ACT ON BEHALF OF SUCH ORGANIZATION AND THAT YOUR ACCEPTANCE OF THE TERMS OF THIS AGREEMENT CREATES A LEGALLY ENFORCEABLE OBLIGATION OF THE ORGANIZATION. AS USED HEREIN, "YOU" AND "YOUR" REFER TO YOU AND ANY ORGANIZATION ON BEHALF OF WHICH YOU ARE ACTING.

Subject to the terms and conditions contained in this Agreement, you, your employees and agents are authorized to use CDT only as contained in the following authorized materials and solely for internal use by yourself, employees and agents within your organization within the United States and its territories. Use of CDT is limited to use in programs administered by Centers for Medicare & Medicaid Services (CMS). You agree to take all necessary steps to ensure that your employees and agents abide by the terms of this agreement. You acknowledge that the ADA holds all copyright, trademark and other rights in CDT. You shall not remove, alter, or obscure any ADA copyright notices or other proprietary rights notices included in the materials.

Any use not authorized herein is prohibited, including by way of illustration and not by way of limitation, making copies of CDT for resale and/or license, transferring copies of CDT to any party not bound by this agreement, creating any modified or derivative work of CDT, or making any commercial use of CDT. License to use CDT for any use not authorized herein must be obtained through the American Dental Association, 211 East Chicago Avenue, Chicago, IL 60611. Applications are available at the ADA website.

Applicable Federal Acquisition Regulation Clauses (FARS)\Department of restrictions apply to Government Use.

ADA DISCLAIMER OF WARRANTIES AND LIABILITIES: CDT is provided "as is" without warranty of any kind, either expressed or implied, including but not limited to, the implied warranties of merchantability and fitness for a particular purpose. No fee schedules, basic unit, relative values or related listings are included in CDT. The ADA does not directly or indirectly practice medicine or dispense dental services. The sole responsibility for the software, including any CDT and other content contained therein, is with (insert name of applicable entity) or the CMS; and no endorsement by the ADA is intended or implied. The ADA expressly disclaims responsibility for any consequences or liability attributable to or related to any use, non-use, or interpretation of information contained or not contained in this file/product. This Agreement will terminate upon notice to you if you violate the terms of this Agreement. The ADA is a third party beneficiary to this Agreement.

CMS DISCLAIMER: The scope of this license is determined by the ADA, the copyright holder. Any questions pertaining to the license or use of the CDT should be addressed to the ADA. End Users do not act for or on behalf of the CMS. CMS DISCLAIMS RESPONSIBILITY FOR ANY LIABILITY ATTRIBUTABLE TO END USER USE OF THE CDT. CMS WILL NOT BE LIABLE FOR ANY CLAIMS ATTRIBUTABLE TO ANY ERRORS, OMISSIONS, OR OTHER INACCURACIES IN THE INFORMATION OR MATERIAL COVERED BY THIS LICENSE. In no event shall CMS be liable for direct, indirect, special, incidental, or consequential damages arising out of the use of such information or material.

End Disclaimer


This website provides information and news about the Medicare program for health care professionals only. All communication and issues regarding your Medicare benefits are handled directly by Medicare and not through this website. For the most comprehensive experience, we encourage you to visit Medicare.gov or call 1-800-MEDICARE. In the event your provider fails to submit your Medicare claim, please view these resources for claim assistance.
Join eNews       En Español
Text Size:
YouTube LinkedIn Email Print
Send a link to this page
[Multiple email addresses must be separated by a semicolon.]
Last Modified: 11/18/2024 Location: FL, PR, USVI Business: Part A

Remedy lump sum payment for the 340B-acquired drug payment policy for calendar years 2018-2022 Q&As

Q: What is the 340B drug discount program?
A: The 340B drug discount program was established under Section 340B of the Public Health Services Act (PHSA) and allows covered entities to purchase certain outpatient drugs and biologicals at discounted prices from drug manufacturers.
Q: What was the 340B drug payment policy?
A: The 340B OPPS drug payment policy started in 2018. The policy reduced the amount of reimbursement paid by Medicare to 340B covered entity hospitals for 340B drugs under OPPS.
Prior to 2018, the Medicare payment rate for all Part B covered outpatient drugs provided in outpatient hospitals was the statutory default—generally average sales price (ASP) plus 6% for covered outpatient drugs. A 340B covered entity hospital would acquire an outpatient drug from a manufacturer at the 340B discounted rate and then be reimbursed by Medicare for that drug at ASP plus 6%.
Starting in 2018, CMS adjusted the payment rate for 340B drugs and generally paid for certain separately payable drugs acquired through the 340B Program at ASP minus 22.5% to more accurately reflect the actual costs incurred by participating hospitals in acquiring 340B drugs.
Q: When did the 340B payment policy end?
A: The reduced payment rate for 340B drugs was in effect from January 1, 2018, through September 27, 2022. From September 28, 2022, forward, hospitals participating in the 340B program have been paid the statutory default—generally ASP plus 6%—for drugs acquired through the 340B drug pricing program.
Q: Why did the 340B payment policy end?
A: The 340B drug payment policy ended after the Supreme Court held that because CMS had not conducted a survey of hospitals’ acquisition costs, it could not vary the payment rates for outpatient prescription drugs by hospital group.
Q: What does the 340B Remedy Final Rule do?
A: The 340B remedy final rule aims to place affected 340B providers in as close to the same
position as if the 340B payment policy had not existed during calendar year (CY) 2018 through CY 2022 as is administratively feasible. To do so, the final rule with comment period (88 FR 77150) external link ensures affected 340B providers receive the $9.0 billion remedy payments for 340B drug payments that they would have received if the original 340B payment policy finalized in CY 2018 had not existed ($1.6 billion of the $10.6 billion has already been paid as processed or reprocessed CY 2022 claims), and (2) prospectively offsets $7.8 billion, which is primarily to address the non-drug item and service payments increased from CY 2018 through CY 2022 as a direct result of the 340B drug payment policy in order to maintain budget neutrality.
Q: Will this remedy impact beneficiary co-payments on the 340B drugs between CY 2018 to CY 2022?
A: Beneficiary co-payments should not increase as a result of this remedy rule. Affected 340B covered entity hospitals have been instructed not to bill beneficiaries for coinsurance on remedy payments because they are remedy payments issued through MAC instructions relying in part on our equitable adjustment authority under section 1833(t)(2)(E) of the Social Security Act and thus analogous to the type of cost report adjustments we have previously found not to be subject to beneficiary copayments.
Q: What does the remedy mean for 340B-acquired drugs moving forward?
A: This final rule does not impact OPPS payment for 340B-acquired drugs in CY 2023 or future years. This remedy ensures that all hospitals, including affected 340B entity hospitals, will receive the approximate payment they would have received if the original 340B payment policy, established in calendar year 2018, did not exist.
Q: When will CMS make the lump sum payments?
A: MACs will begin payment on January 8, 2024. It is anticipated that MACs will make all payments no later than February 7, 2024, except for, at CMS’s direction, payments for which a technical correction request has been requested by a hospital as discussed below.
Q: Is CMS paying interest on the remedy payments or collecting interest through the prospective offset?
A: No, CMS is not paying or collecting interest.
Q: Can a hospital request a correction to the lump sum payment amount calculated in Addendum AAA?
A: No. The deadline (November 30, 2023) for affected hospitals to request a technical correction to any errors on their lump sum payment amount in Addendum AAA has passed. A few hospitals requested a technical correction. CMS will inform the relevant MACs of the amount to be paid to these hospitals once the technical correction request has been addressed by CMS.
Q: Does the 340B drug remedy lump sum payment include an amount equal to the beneficiary coinsurance portion that affected 340B covered entity hospitals would have received had the original 340B payment policy never existed?
A: Yes, the 340B remedy payment includes an amount equal to the beneficiary coinsurance portion that affected 340B covered entity hospitals would have received had the original 340B payment policy never existed.
Q: My hospital did not participate in the 340B Program from calendar year 2018 to calendar year 2022 but was identified on Addendum AAA as eligible for payment. Is there an error that the hospital is receiving a lump sum remedy payment?
A: No. Our calculations are based on the information that hospitals themselves originally used when submitting claims with the 340B billing modifier, “JG.” Any hospitals that used the 340B billing modifier “JG” for claims during the time period in which the 340B Payment Policy was in effect received reduced payments under the 340B Payment Policy. Our analysis suggests that these hospitals may have erroneously included the “JG” modifier when initially submitting claims. We are making remedy payments even to providers who submitted the “JG” modifier incorrectly, because they received reduced payments under the 340B Payment Policy.
Q: Why does the remedy payment my hospital received not match the amount on Addendum AAA that was published with the 340B Remedy Final Rule?
A: All remedy payments are subject to the MAC’s normal accounting procedures and may in effect be combined with other payment released on the same date and /or include any applicable outstanding Medicare offsets that are the result of provider-specific overpayment obligations, adjustments resulting from errors identified through the lump-sum technical correction process, any of which may impact the provider’s net payment amount.
Q: How will the 340B remedy payment affect the cost report?
A: The MAC will not include these lump sum payments on any cost report.
First Coast Service Options (First Coast) strives to ensure that the information available on our provider website is accurate, detailed, and current. Therefore, this is a dynamic site and its content changes daily. It is best to access the site to ensure you have the most current information rather than printing articles or forms that may become obsolete without notice.